← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Altravax, Inc.
Fargo, ND
$9,246,015
Total funding
13
Grants
Funding over time
peak $2M · FY2007–16$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$10,238,267 · 14
By mechanism
R43$5,894,375 · 11
R01$2,818,802 · 1
P01$992,252 · 1
R41$532,838 · 1
Investigators at Altravax, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Development of Novel Immunogens for Vaccines to HIV-1$992,252
P01 · FY2009 · AI
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-$840,676
R01 · FY2014 · AI
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-$828,847
R01 · FY2015 · AI
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-$597,816
R01 · FY2012 · AI
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-$551,463
R01 · FY2013 · AI
A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus$532,838
R41 · FY2015 · AI
Vaccines for Eastern and Western Equine Encephalitis Viruses$502,847
R43 · FY2007 · AI
Novel Tetravalent Vaccines for Dengue Virus$300,000
R43 · FY2012 · AI
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-$300,000
R43 · FY2013 · AI
Novel Subunit Vaccines against Varicella Zoster Virus$300,000
R43 · FY2014 · AI
Development of a Universal Influenza B Vaccine$300,000
R43 · FY2016 · AI
Development of a Universal Influenza B Vaccine$300,000
R43 · FY2015 · AI
Improved Vaccines for Influenza B Virus$300,000
R43 · FY2011 · AI
Novel Vaccine Immunogens for Pandemic H5 Influenza$300,000
R43 · FY2009 · AI
Novel Therapeutic Vaccines for Chronic HBV$300,000
R43 · FY2013 · AI
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-$300,000
R43 · FY2012 · AI
Novel Therapeutic Vaccines for Chronic HBV$300,000
R43 · FY2012 · AI
VLP-Based Antibody-Inducing Vaccines for HIV-1$299,928
R43 · FY2011 · AI
VLP-Based Antibody-Inducing Vaccines for HIV-1$299,760
R43 · FY2010 · AI
Designing Improved HIV-1 Envelope Proteins as Vaccine Candidates$299,760
R43 · FY2010 · AI